Assesses microvascular inflammation effect on allograft loss in kidney transplant recipients, suggesting limited impact without DSA.
Background: Microvascular inflammation (sum of glomerulitis (g) and peritubular capillaritis (ptc) scores ≥2) frequently occurs without donor-specific anti-HLA antibodies (DSA), often alongside T-cell–mediated rejection (TCMR), yet its independent prognostic significance remains uncertain. Methods: In a consecutive single-center cohort of 689 kidney transplant recipients (2004–2021), we examined the impact of first g+ptc≥2, TCMR, and de novo DSA (dnDSA) events on death-censored allograft loss using Cox models with time-dependent covariates to account for event timing and overlap. Results: A first g+ptc≥2 occurred in 106/689 (15%) recipients, and 88% had concomitant or sequential TCMR and/or dnDSA. Most g+ptc≥2 biopsies were associated with TCMR (76%), including those with g=0. When assessed individually, the first g+ptc≥2 (HR 4.33, 95%CI 2.5-7.5), TCMR (HR 4.07, 95%CI 2.3-7.1), and dnDSA (HR 4.26, 95%CI 2.2-8.3) events were each associated with death-censored allograft loss. However, in a combined time-dependent model, first TCMR (HR 2.74, 95%CI 1.4-5.4) and dnDSA (HR 2.32, 95%CI 1.1-5.1) remained independently associated with death-censored allograft loss, whereas g+ptc≥2 did not (HR 1.77, 95%CI 0.84-3.73). Conclusions: In a modern tacrolimus-based cohort, g+ptc≥2 without DSA was not associated with worse outcomes after adjustment for serial or concomitant TCMR and dnDSA events.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: